Research

New KRAS-Targeted Drug Shows Real Promise for Pancreatic Cancer Patients

A new drug called daraxonrasib targets KRAS mutations found in over 90% of pancreatic cancers, showing a 47% response rate and 83% six-month overall survival in an early clinical trial.